Candidate for Dermatitis
NCT10004 quickly reduced scratching to near-baseline levels in multiple mouse models of contact dermatitis including a repeat dose studies. More importantly, it also effectively reduced the amount of scratching observed in a canine model of atopic dermatitis was induced through application of house dust mite allergens. This model is the gold-standard in evaluation of therapeutics for itch related to atopic dermatitis.
Candidate for Additional Itch Applications
NCT10004 eliminates itch by restoring signal regulation in the dorsal horn. Because of this, it is expected to be effective against most types of itch. Indeed, NCT10004 shows excellent efficacy in several non-dermatitis models of itch. As a result, NCT10004 may find use in treating many disorders including uremic pruritus, chloeostatic pruritus, opioid-related itch, psoriasis, neurogenic itch, and other itchy skin diseases.
Creating Long-Term Value
In addition to the significant value NCT10004 creates as a potential new treatment for dermatitis and other itch related disorders, it may provide additional value through its use in human clinical proof-of-concept studies. The goal of these studies would be to identify new indications that could be targeted by a follow-on program.
For example, pain has historically been difficult to translate from efficacy in preclinical models to clinical efficacy. NCT10004, could be tested in small scale experimental studies to evaluate whether its mechanism of action is effective in specific types of pain. This data could then be used to support a follow-on program specifically tailored to the newly identified indication.